Alex Rovira
Multiple sclerosis (MS) is a chronic, persistent inflammatory-demyelinating disease of the central nervous system (CNS), characterized pathologically by areas of inflammation, demyelination, axonal loss, and gliosis scattered throughout the CNS. The disease has a predilection for the optic nerves, brain stem, spinal cord, and cerebellar and periventricular white matter, though cortical and subcortical gray … more »
Françoise Durand-Dubief
The primary objective of our work was to study the loss of the overall brain volume, ie, brain atrophy, as a potential marker of neurodegeneration in patients with multiple sclerosis (MS). Our hypothesis was that overall brain atrophy, a possible index peculiar to each patient, would be predictive of long-term disability. This hypothesis was … more »
Roberto Cappellani
Robert Zivadinov
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system in young people. Conventional MRI is an important tool not only for determining the early diagnosis of MS but also for monitoring disease progression. However, pathology … more »
Massimiliano Calabrese
Several studies pointed out that gray matter damage in multiple sclerosis (MS) is not a late phenomenon. It appears to start early in the disease course, sometimes already at clinical onset. However, because it is often impossible to date the biological/subclinical onset of MS, which in adult patients may precede its clinical onset by some … more »
Philipp Sämann
For patients with multiple sclerosis (MS), MRI has gained an essential role in treatment management. In particular, quantitative markers of neuroaxonal damage have emerged as long-term predictors of MS-related disability and as surrogate markers of immunomodulatory efficacy.1 Exceeding a certain threshold of neuroaxonal pathology might accelerate a patient’s transition to secondary-progressive MS or … more »
Robert Zivadinov
There is a growing interest in studying the extent of cortical and subcortical deep gray matter pathology (SDGM) starting from the earliest clinical stages of multiple sclerosis (MS). The relationship between the appearance of white matter (WM) lesions and SDGM atrophy in patients with MS is not well-understood. A number of independent studies have shown that … more »
Mattias Vågberg
The importance of brain atrophy in neurodegenerative disorders is well-known. Considering the example of multiple sclerosis (MS), brain atrophy has been shown to be a valuable biomarker both for prognostic considerations and for measuring treatment effect. Although determination of brain atrophy is widely used in research regarding MS, it has not yet found … more »